{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T01:31:55Z","timestamp":1675128715465},"reference-count":64,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.3892\/etm.2016.3610","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T04:34:31Z","timestamp":1471926871000},"page":"2265-2274","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism"],"prefix":"10.3892","volume":"12","author":[{"given":"Xiaowei","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,8,23]]},"reference":[{"key":"key20180108132625_b1-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ccc.2011.09.006","article-title":"Epidemiology and incidence: The scope of the problem and risk factors for development of venous thromboembolism","volume":"27","author":"Stein","year":"2011","journal-title":"Crit Care Clin"},{"key":"key20180108132625_b2-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.amjmed.2011.05.025","article-title":"Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism","volume":"125","author":"Stein","year":"2012","journal-title":"Am J Med"},{"key":"key20180108132625_b3-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.amjmed.2011.10.015","article-title":"Thrombolytic therapy in unstable patients with acute pulmonary embolism: Saves lives but underused","volume":"125","author":"Stein","year":"2012","journal-title":"Am J Med"},{"key":"key20180108132625_b4-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.amjmed.2011.12.003","article-title":"Case fatality rate with pulmonary embolectomy for acute pulmonary embolism","volume":"125","author":"Stein","year":"2012","journal-title":"Am J Med"},{"key":"key20180108132625_b5-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"PLIFY-EXT Investigators: Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180108132625_b6-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180108132625_b7-etm-0-0-3610","first-page":"e152S","article-title":"American College of Chest Physicians: Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence","volume":"141","author":"Holbrook","year":"2012","journal-title":"Based Clin Pract Guidelines"},{"key":"key20180108132625_b8-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2011.08753.x","article-title":"British Committee for Standards in Haematology: Guidelines on oral anticoagulation with warfarin-fourth edition","volume":"154","author":"Keeling","year":"2011","journal-title":"Br J Haematol"},{"key":"key20180108132625_b9-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11239-013-1011-z","article-title":"Bleeding complications related to warfarin treatment: A descriptive register study from the anticoagulation clinic at Helsingborg hospital","volume":"38","author":"Navgren","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"key20180108132625_b10-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.amjcard.2013.04.013","article-title":"Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation","volume":"112","author":"Nelson","year":"2013","journal-title":"Am J Cardiol"},{"key":"key20180108132625_b11-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.amjmed.2014.05.023","article-title":"SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation","volume":"127","author":"Gallego","year":"2014","journal-title":"Am J Med"},{"key":"key20180108132625_b12-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.thromres.2014.02.031","article-title":"Mechanical heart valve prosthesis and warfarin-treatment quality and prognosis","volume":"133","author":"Grzymala-Lubanski","year":"2014","journal-title":"Thromb Res"},{"key":"key20180108132625_b13-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11239-013-0900-5","article-title":"Vitamin K antagonists and time in the therapeutic range: Implications, challenges and strategies for improvement","volume":"35","author":"Hylek","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"key20180108132625_b14-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0002-9149(01)01582-X","article-title":"Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement","volume":"88","author":"Ageno","year":"2001","journal-title":"Am J Cardiol"},{"key":"key20180108132625_b15-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.1378\/chest.08-0674","article-title":"American College of Chest Physicians: Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Schulman","year":"2008","journal-title":"Chest"},{"key":"key20180108132625_b16-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-138-9-200305060-00007","article-title":"Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low molecular weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial","volume":"138","author":"Kovacs","year":"2003","journal-title":"Ann Intern Med"},{"key":"key20180108132625_b17-etm-0-0-3610","first-page":"CD007699","article-title":"Warfarin initiation nomograms for venous thromboembolism","volume":"29","author":"Garcia","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key20180108132625_b18-etm-0-0-3610","first-page":"CD007699","article-title":"Warfarin initiation nomograms for venous thromboembolism","volume":"10","author":"Garcia","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key20180108132625_b19-etm-0-0-3610","article-title":"Optimal loading dose of warfarin for the initiation of oral anticoagulation","volume":"12","author":"Mahtani","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key20180108132625_b20-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ajem.2010.07.008","article-title":"High doses of warfarin are more beneficial than its low doses in patients with deep vein thrombosis","volume":"29","author":"Farahmand","year":"2011","journal-title":"Am J Emerg Med"},{"key":"key20180108132625_b21-etm-0-0-3610","first-page":"CD008685","article-title":"Optimal loading dose of warfarin for the initiation of oral anticoagulation","volume":"12","author":"Mahtani","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key20180108132625_b22-etm-0-0-3610","first-page":"S225","article-title":"The efficacy of 3-mg warfarin initiating dose in adult Thai patients, who required long-term anticoagulant therapy","volume":"94","author":"Suwanawiboon","year":"2011","journal-title":"J Med Assoc Thai"},{"key":"key20180108132625_b23-etm-0-0-3610","first-page":"76","article-title":"Chinese Expert Consensus of warfarin anticoagulant therapy","volume":"1","author":"Hu","year":"2013","journal-title":"Zhong Hua Nei Ke Za Zhi"},{"key":"key20180108132625_b24-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11239-012-0811-x","article-title":"Comparison of initial warfarin response in obese patients versus non-obese patients","volume":"36","author":"Wallace","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"key20180108132625_b25-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/1060028013517541","article-title":"Warfarin dosing and body mass index","volume":"48","author":"Mueller","year":"2014","journal-title":"Ann Pharmacother"},{"key":"key20180108132625_b26-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1345\/aph.1A372","article-title":"Assessment of an age-adjusted warfarin initiation protocol","volume":"37","author":"Roberts","year":"2003","journal-title":"Ann Pharmacother"},{"key":"key20180108132625_b27-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2125.2012.04259.x","article-title":"Influence of adult age on the total and free clearance and protein binding of (R)-and (S)-warfarin","volume":"74","author":"Jensen","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"key20180108132625_b28-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1161\/CIRCULATIONAHA.112.101808","article-title":"Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: An analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial","volume":"126","author":"Van Spall","year":"2012","journal-title":"Circulation"},{"key":"key20180108132625_b29-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1185\/030079906X132479","article-title":"Does heart failure exacerbation increase response to warfarin? A critical review of the literature","volume":"22","author":"Self","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"key20180108132625_b30-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-135-6-200109180-00008","article-title":"Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin","volume":"135","author":"Hylek","year":"2001","journal-title":"Ann Intern Med"},{"key":"key20180108132625_b31-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1556\/OH.2009.28674","article-title":"The role of vitamin D in the development of cardiac failure","volume":"150","author":"Szab\u00f3","year":"2009","journal-title":"Orv Hetil"},{"key":"key20180108132625_b32-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00007611-194804000-00018","article-title":"The use of dicumarol as an adjunct to the treatment of congestive heart failure; results in a controlled series of 61 cases","volume":"41","author":"Anderson","year":"1948","journal-title":"South Med J"},{"key":"key20180108132625_b33-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-24-4-648","article-title":"Serial prothrombin estimations in cardiac patients; diagnostic and therapeutic implications; use of dicumarol","volume":"24","author":"Cotlove","year":"1946","journal-title":"Ann Intern Med"},{"key":"key20180108132625_b34-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM194811042391902","article-title":"Dicoumarol therapy in congestive heart failure","volume":"239","author":"Wishart","year":"1948","journal-title":"N Engl J Med"},{"key":"key20180108132625_b35-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1378\/chest.10-0777","article-title":"Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis","volume":"139","author":"Nathisuwan","year":"2011","journal-title":"Chest"},{"key":"key20180108132625_b36-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cpt1979253309","article-title":"Smoking and warfarin disposition","volume":"25","author":"Bachmann","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"key20180108132625_b37-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00228-006-0124-0","article-title":"Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin","volume":"62","author":"Kim","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"key20180108132625_b38-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0897190013516501","article-title":"Patient case: Impact of smoking cessation on international normalized ratio","volume":"27","author":"Jordan","year":"2014","journal-title":"J Pharm Pract"},{"key":"key20180108132625_b39-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1345\/aph.10226","article-title":"Increase in international normalized ratio associated with smoking cessation","volume":"35","author":"Colucci","year":"2001","journal-title":"Ann Pharmacother"},{"key":"key20180108132625_b40-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1345\/aph.1E381","article-title":"Anticoagulation working group: Search for predictors of nontherapeutic INR results with warfarin therapy","volume":"39","author":"McGriff-Lee","year":"2005","journal-title":"Ann Pharmacother"},{"key":"key20180108132625_b41-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/hepr.12093","article-title":"Usefulness and accuracy of the international normalized ratio and activity percent of prothrombin time in patients with liver disease","volume":"44","author":"Takikawa","year":"2014","journal-title":"Hepatol Res"},{"key":"key20180108132625_b42-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11239-008-0211-4","article-title":"Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: A retrospective study of 1,043 cases","volume":"27","author":"Denas","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"key20180108132625_b43-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/FJC.0b013e31826f34f3","article-title":"International normalized ratio decreases after hemodialysis treatment in patients treated with warfarin","volume":"60","author":"Abe","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"key20180108132625_b44-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0009-9236(03)00015-8","article-title":"Cytochrome P4502C9 activity in end-stage renal disease","volume":"73","author":"Dreisbach","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"key20180108132625_b45-etm-0-0-3610","first-page":"1012","article-title":"Can acute renal insufficiency increase the effect of warfarin?","volume":"171","author":"Arnason","year":"2009","journal-title":"Ugeskr Laeger"},{"key":"key20180108132625_b46-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.ajkd.2010.05.023","article-title":"Warfarin dosing in patients with impaired kidney function","volume":"56","author":"Limdi","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key20180108132625_b47-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/phar.1445","article-title":"Evaluation of warfarin dose requirements in patients with chronic kidney disease and end-stage renal disease","volume":"34","author":"Sakaan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key20180108132625_b48-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"American College of Chest Physicians: Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th edition, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"key20180108132625_b49-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11606-005-0113-5","article-title":"The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens","volume":"20","author":"Glasheen","year":"2005","journal-title":"J Gen Intern Med"},{"key":"key20180108132625_b50-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.amjmed.2014.01.044","article-title":"Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans","volume":"127","author":"Lane","year":"2014","journal-title":"Am J Med"},{"key":"key20180108132625_b51-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1592\/phco.23.8.1079.32883","article-title":"Effect of levofloxacin co-coadministration on the international normalized ratios during warfarin therapy-a comment","volume":"23","author":"Glasheen","year":"2003","journal-title":"Pharmacotherapy"},{"key":"key20180108132625_b52-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1592\/phco.23.3.333.32101","article-title":"Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy","volume":"23","author":"Yamreudeewong","year":"2003","journal-title":"Pharmacotherapy"},{"key":"key20180108132625_b53-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamainternmed.2013.13957","article-title":"Warfarin-Associated Research Projects and Other Endeavors Consortium: Warfarin interactions with antibiotics in the ambulatory care setting","volume":"174","author":"Clark","year":"2014","journal-title":"JAMA Intern Med"},{"key":"key20180108132625_b54-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.amjmed.2014.01.044","article-title":"Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans","volume":"127","author":"Lane","year":"2014","journal-title":"Am J Med"},{"key":"key20180108132625_b55-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"key20180108132625_b56-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2125.2000.00240.x","article-title":"First trimester exposure to cefuroxime: A prospective cohort study","volume":"50","author":"Berkovitch","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"key20180108132625_b57-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjmed.2009.07.020","article-title":"Fibrate\/statin initiation in warfarin users and gastrointestinal bleeding risk","volume":"123","author":"Schelleman","year":"2010","journal-title":"Am J Med"},{"key":"key20180108132625_b58-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1055\/s-0037-1613486","article-title":"The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements","volume":"89","author":"Hickmott","year":"2003","journal-title":"Thromb Haemost"},{"key":"key20180108132625_b59-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/0002-9343(50)90290-7","article-title":"Hypercoagulability of blood associated with ACTH and cortisone therapy","volume":"9","author":"Cosgriff","year":"1950","journal-title":"Am J Med"},{"key":"key20180108132625_b60-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-132-8-200004180-00005","article-title":"Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone","volume":"132","author":"Costedoat-Chalumcau","year":"2000","journal-title":"Ann Intern Med"},{"key":"key20180108132625_b61-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/135245859700300406","article-title":"Treatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin","volume":"3","author":"Kaufman","year":"1997","journal-title":"Mult Scler"},{"key":"key20180108132625_b62-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/(SICI)1096-8652(199809)59:1<22::AID-AJH5>3.0.CO;2-1","article-title":"Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population","volume":"59","author":"Brigden","year":"1998","journal-title":"Am J Hematol"},{"key":"key20180108132625_b63-etm-0-0-3610","doi-asserted-by":"crossref","first-page":"957362","DOI":"10.1155\/2014\/957362","article-title":"Updates on the clinical evidenced herb-warfarin interactions","volume":"2014","author":"Ge","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"key20180108132625_b64-etm-0-0-3610","first-page":"1211","article-title":"Warfarin interactions with medicinal herbs","volume":"9","author":"Mili\u0107","year":"2014","journal-title":"Nat Prod Commun"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2016.3610\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T17:40:56Z","timestamp":1568310056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2016.3610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,23]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,8,23]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.3892\/etm.2016.3610"],"URL":"https:\/\/doi.org\/10.3892\/etm.2016.3610","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,23]]}}}